Business

Announcement on Voluntary Disclosure of First Subject Enrollment in the Phase III Clinical Trial of Lenconelontuzumab/Yizekang (BL-B01D1/iza-bren) Combination Therapy for First-Line Extensive-Stage Small Cell Lung Cancer

Announcement on Voluntary Disclosure of First Subject Enrollment in the Phase III Clinical Trial of Lenconelontuzumab/Yizekang (BL-B01D1/iza-bren) Combination Therapy for First-Line Extensive-Stage Small Cell Lung Cancer

articleSichuan Biokin Pharmaceutical Co., Ltd. Class AJune 25, 20265/news/announcement-on-voluntary-disclosure-of-first-subject-enrollment-in-the-phase-iii-clinical-trial-of-lenconelontuzumabyizekang-bl-b01d1iza-bren-combination-therapy-for-first-line-extensive-stage-small-cell-lung-cancer
Announcement on Voluntary Disclosure of First Subject Enrollment in the Phase III Clinical Trial of Lenconelontuzumab/Yizekang (BL-B01D1/iza-bren) Combination Therapy for First-Line Extensive-Stage Small Cell Lung Cancer

About this update from Sichuan Biokin Pharmaceutical Co., Ltd. Class A

Announcement on Voluntary Disclosure of First Subject Enrollment in the Phase III Clinical Trial of Lenconelontuzumab/Yizekang (BL-B01D1/iza-bren) Combination Therapy for First-Line Extensive-Stage Small Cell Lung Cancer The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Sichuan Biokin Pharmaceutical Co., Ltd. Class A